NR1H4 and metabolic dysfunction-associated steatotic liver disease: Gut microbiota metabolites (such as SCFAs, BAs, and tryptophan derivatives) and bacterial/fungal components (such as cytolysi, candidalysin, and β‐glucan) profoundly influence the disease progression of ALD and MASLD by regulating key receptors and signaling pathways such as farnesoid X receptor (FXR), AMPK, and PPARα.